China In-Vitro Diagnostics Market 2019-2023 - Growth Opportunities, Regulatory Developments, Strategic Imperatives

DUBLIN, Sept. 10, 2019 /PRNewswire/ -- The "Chinese In-Vitro Diagnostics Market Insight, Forecast to 2023" report has been added to's offering.

The In-vitro Diagnostics (IVD) market in China shows strong growth potential in several segments. Market growth is set to be driven by the growing volume of tests, rather than the higher price of testing solutions in traditional segments and the popularization of advanced testing technology in emerging segments. In the context of the reform in public hospitals, the IVD industry is the direct beneficiary of the drug price policy and is expected to acquire strong growth potential in the long run.

On the supply side, foreign companies are dominating the high-end market by leveraging their technical advantage to develop closed-end systems for their automatic analyzers. However, owing to their lack of input on distribution channels and their high-priced products, they are likely to find it difficult to penetrate the lower-end hospitals in the short term.

The IVD market in China presents a diversified growth potential for the different tiers of competitors: domestic participants gain from the growth momentum for the low-end market, whereas leading foreign manufacturers dominate the high-end market, which is expected to become the new emerging market along with ever-improving localized services to meet various demands. The mid-to-low-end market is crowded with local participants, leading to fierce competition.

China is currently facing a severe shortage of anatomic pathologists, which blocks patients' access to quality care. The relatively small number of pathologists are often overworked. Moreover, the penetration of IVD devices has been on the lower side. China has not yet issued a regulation on management standards for independent clinical laboratories. This leads to each laboratory developing its own standards that are not uniform and providing a narrow scope of services (which is not in line with accepted clinical laboratory standards).

Overall, the substitution devices developed by local companies are the most important factor in increasing the IVD market size, as it improves the accessibility of lower-end hospitals to advanced IVD technologies, boosting their need to update IVD products.

Key Issues Addressed

    --  What are the key healthcare trends that can impact the Chinese IVD
    --  What are the drivers and restraints impacting market growth?
    --  What are the unmet needs and opportunities for the existing and emerging
    --  What are the segment shares of key market participants?
    --  How are companies dealing with market challenges?
    --  What are the future trends and forecast scenario for IVD in China?

Key Topics Covered:

1. Executive Summary

    --  Key Findings
    --  Scope and Segmentation
    --  Key Questions this Study will Answer
    --  Chinese IVD Market Attractiveness Matrix by Segment

2. Market Drivers and Restraints

    --  Market Drivers
    --  Market Restraints

3. Chinese IVD Market - An Overview

    --  Market Overview
    --  Chinese IVD Market - Market Forecast
    --  Revenue Forecast Discussion

4. Competitive Environment

5. Growth Opportunities and Regulatory Consideration (Top 3 Segments) - Chinese IVD Market

    --  Growth Opportunities in Clinical Diagnostics
    --  Regulatory Developments in China
    --  Strategic Imperatives for IVD Vendors

6. Immunochemistry - Segment Breakdown

    --  Opportunities and Challenges - Digitalization of Distribution Channels
    --  Revenue Forecast
    --  Revenue Forecast Discussion
    --  Market Share Analysis

7. Molecular Diagnostics - Segment Breakdown

8. POCT - Segment Breakdown

9. Top Predictions and Conclusion

    --  Top Predictions for the Chinese IVD Market
    --  Key Conclusion
    --  Legal Disclaimer

10. Appendix - Chinese IVD Market

    --  Timeline of Key Reforms Driving Private Sector Participation
    --  Health Insurance Programs in China - An Overview
    --  Healthy China 2020 Initiative - An Overview
    --  Total Healthcare Spending in China
    --  Encouraging Private Foreign Investments in China's Hospital System
    --  Allowing Physicians to Practice at Multiple Sites
    --  Allowing Public Hospital Patients to be Treated in Private Hospitals
    --  Providing Structured Guidelines for Medical Devices and Clinical Tests
    --  Market Attractiveness - Key Parameters
    --  List of Exhibits

For more information about this report visit

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

View original content:

SOURCE Research and Markets